706 related articles for article (PubMed ID: 30092967)
1. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
[TBL] [Abstract][Full Text] [Related]
2. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.
Bowles EJ; Wellman R; Feigelson HS; Onitilo AA; Freedman AN; Delate T; Allen LA; Nekhlyudov L; Goddard KA; Davis RL; Habel LA; Yood MU; McCarty C; Magid DJ; Wagner EH;
J Natl Cancer Inst; 2012 Sep; 104(17):1293-305. PubMed ID: 22949432
[TBL] [Abstract][Full Text] [Related]
3. Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score‒Matched Cohort Study.
Abdel-Qadir H; Bobrowski D; Zhou L; Austin PC; Calvillo-Argüelles O; Amir E; Lee DS; Thavendiranathan P
J Am Heart Assoc; 2021 Jan; 10(2):e018393. PubMed ID: 33401953
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Therapy-Related Cardiac Dysfunction in Adult Women Treated in Routine Clinical Practice: A Population-Based Cohort Study.
Thavendiranathan P; Abdel-Qadir H; Fischer HD; Camacho X; Amir E; Austin PC; Lee DS
J Clin Oncol; 2016 Jul; 34(19):2239-46. PubMed ID: 27091709
[TBL] [Abstract][Full Text] [Related]
5. The Temporal Risk of Heart Failure Associated With Adjuvant Trastuzumab in Breast Cancer Patients: A Population Study.
Goldhar HA; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Pal RS; Brezden-Masley C; Gavura S; Lien K; Chan KK
J Natl Cancer Inst; 2016 Jan; 108(1):. PubMed ID: 26476433
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-related cardiotoxicity among older patients with breast cancer.
Chavez-MacGregor M; Zhang N; Buchholz TA; Zhang Y; Niu J; Elting L; Smith BD; Hortobagyi GN; Giordano SH
J Clin Oncol; 2013 Nov; 31(33):4222-8. PubMed ID: 24127446
[TBL] [Abstract][Full Text] [Related]
7. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
Matos E; Jug B; Blagus R; Zakotnik B
Arq Bras Cardiol; 2016 Jul; 107(1):40-7. PubMed ID: 27305108
[TBL] [Abstract][Full Text] [Related]
8. Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study.
Jacobse JN; Schaapveld M; Boekel NB; Hooning MJ; Jager A; Baaijens MHA; Hauptmann M; Russell NS; Rutgers EJT; Aleman BMP; Sonke GS; van Leeuwen FE
Breast Cancer Res Treat; 2021 Jan; 185(1):205-214. PubMed ID: 32964358
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data.
Leung HW; Chan AL
Expert Opin Drug Saf; 2015; 14(11):1661-71. PubMed ID: 26461271
[TBL] [Abstract][Full Text] [Related]
10. Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study.
Kaboré EG; Guenancia C; Vaz-Luis I; Di Meglio A; Pistilli B; Coutant C; Cottu P; Lesur A; Petit T; Dalenc F; Rouanet P; Arnaud A; Arsene O; Ibrahim M; Wassermann J; Boileau-Jolimoy G; Martin AL; Lemonnier J; André F; Arveux P
PLoS Med; 2019 Dec; 16(12):e1002989. PubMed ID: 31869400
[TBL] [Abstract][Full Text] [Related]
11. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer.
Pinder MC; Duan Z; Goodwin JS; Hortobagyi GN; Giordano SH
J Clin Oncol; 2007 Sep; 25(25):3808-15. PubMed ID: 17664460
[TBL] [Abstract][Full Text] [Related]
12. Global Longitudinal Strain Accuracy for Cardiotoxicity Prediction in a Cohort of Breast Cancer Patients During Anthracycline and/or Trastuzumab Treatment.
Gripp EA; Oliveira GE; Feijó LA; Garcia MI; Xavier SS; Sousa AS
Arq Bras Cardiol; 2018 Feb; 110(2):140-150. PubMed ID: 29561992
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Monitoring During Adjuvant Trastuzumab-Based Chemotherapy Among Older Patients With Breast Cancer.
Chavez-MacGregor M; Niu J; Zhang N; Elting LS; Smith BD; Banchs J; Hortobagyi GN; Giordano SH
J Clin Oncol; 2015 Jul; 33(19):2176-83. PubMed ID: 25964256
[TBL] [Abstract][Full Text] [Related]
14. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
15. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
[TBL] [Abstract][Full Text] [Related]
16. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
17. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
18. Obesity As a Risk Factor for Anthracyclines and Trastuzumab Cardiotoxicity in Breast Cancer: A Systematic Review and Meta-Analysis.
Guenancia C; Lefebvre A; Cardinale D; Yu AF; Ladoire S; Ghiringhelli F; Zeller M; Rochette L; Cottin Y; Vergely C
J Clin Oncol; 2016 Sep; 34(26):3157-65. PubMed ID: 27458291
[TBL] [Abstract][Full Text] [Related]
19. Cardiac sympathetic hyperactivity after chemotherapy: early sign of cardiotoxicity?
Guimarães SL; Brandão SC; Andrade LR; Maia RJ; Markman Filho B
Arq Bras Cardiol; 2015 Sep; 105(3):228-34. PubMed ID: 26176188
[TBL] [Abstract][Full Text] [Related]
20. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]